Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
Status: | Completed |
---|---|
Conditions: | Ocular, Ocular |
Therapuetic Areas: | Ophthalmology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/21/2018 |
Start Date: | August 29, 2011 |
End Date: | April 28, 2012 |
A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%)
compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118
Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID
for 12 weeks will also be evaluated.
compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118
Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID
for 12 weeks will also be evaluated.
Inclusion Criteria:
- Willing and able to read, sign, and date the informed consent and HIPAA documents
- Willing and able to comply with all study procedures
- Be at least 18 years of age
- Patient-reported history of dry eye in both eyes
- Demonstrate a positive response when exposed to the Controlled Adverse Environment
model
- A negative urine pregnancy test if female of childbearing potential and must use
adequate birth control throughout the study period
Exclusion Criteria:
- Any ocular condition that, in the opinion of the Investigator, could affect study
parameters including, but not limited to, active ocular infection, ocular
inflammation, glaucoma, and/or diabetic retinopathy
- Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the
study period
- Any blood donation or significant loss of blood within 56 days of Visit 1
- Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of
acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
- Use of any topical ophthalmic preparations (including artificial tear substitutes) 72
hrs prior to Visit 1 and during the study
- Any significant chronic illness that could interfere with study parameters
- History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal
refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical
procedure within 12 months prior to Visit 1; or any scheduled ocular surgical
procedure during the study period.
- Known history of alcohol and/or drug abuse
- Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet
cells (as with Vitamin A deficiency)
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials